Sight sciences chief authorized officer sells shares price $17,131

Jeremy B. Hayden, the Chief Authorized Officer of Sight Sciences , Inc. (NASDAQ:SGHT), not too long ago bought 4,864 shares of the corporate’s widespread inventory. The transaction comes because the inventory trades close to its 52-week low of $3.30, with shares down over 45% prior to now six months. The shares had been bought to cowl tax liabilities related to the vesting of restricted inventory models. The sale, executed on January 3, 2025, was performed at a weighted common value of $3.522 per share, amounting to a complete transaction worth of roughly $17,131. Following this transaction, Hayden retains direct possession of 153,823 shares within the firm. Whereas the corporate maintains robust liquidity with a present ratio of 10.18, InvestingPro evaluation reveals the corporate is shortly burning by way of money. Get entry to 10+ further key insights and detailed monetary evaluation with an InvestingPro subscription.

In different current information, Sight Sciences, a medical gadget firm, has secured an extra $5 million in mortgage funding from its present credit score facility with Hercules Capital (NYSE:HTGC), Inc. and associates, elevating the overall borrowed quantity to $40 million. The corporate’s third-quarter income noticed a slight improve of 1% year-over-year to $20.2 million, with surgical glaucoma income accounting for $18.6 million. Nevertheless, surgical glaucoma income noticed a sequential lower of 8%, and dry eye income declined by 4% to $1.5 million. Sight Sciences additionally issued warrants to the lenders, permitting them to buy shares of the corporate’s widespread inventory.

UBS has initiated protection of Sight Sciences with a Purchase ranking, forecasting robust gross sales progress by 2026. The agency expects the corporate’s TearCare Dry Eye answer to drive double-digit gross sales progress and gross margin enlargement that exceeds consensus estimates for 2026 and past. Regardless of present setbacks, Sight Sciences plans to boost gross sales efficiency and strategic positioning, remaining optimistic about progress within the surgical glaucoma and dry eye segments in 2025. These are simply a few of the current developments surrounding Sight Sciences.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.